omeprazole has been researched along with Critical Illness in 19 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Critical Illness: A disease or state in which death is possible or imminent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An allometric size model allows changes to be predicted in all the pharmacokinetic parameters, making dose adjustment by body weight important to achieve the most effective omeprazole exposure." | 5.19 | Population pharmacokinetics of omeprazole in critically ill pediatric patients. ( Carrillo, A; Colom, H; González, R; López, J; López-Herce, J; Manzanares, C; Solana, MJ; Urbano, J, 2014) |
| "Omeprazole is a drug used in the prophylaxis of the gastrointestinal bleeding in these patients, but its cardiovascular effects are unknown." | 2.78 | [Hemodynamic effects of intravenous omeprazole in critically ill children]. ( Botrán, M; Del Castillo, J; Garrido, B; López-Herce, J; Solana, MJ; Urbano, J, 2013) |
| " Sequential blood samples were collected over 24 h to characterize SOS absorption and pharmacokinetic parameters." | 2.70 | A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers. ( Metzler, MH; Miedema, BW; Olsen, KM; Phillips, JO; Rangnekar, NJ; Rebuck, JA, 2001) |
| "Lansoprazole 30 mg was administered once daily with water through a nasogastric tube for 2 days." | 2.69 | Nasogastric lansoprazole is effective in suppressing gastric acid secretion in critically ill patients. ( Chang, CS; Chen, GH; Ko, CW; Poon, SK; Tsai, WL; Yeh, HZ; Yu, HK, 2000) |
| " As there are specific characteristics of these patients that could alter the pharmacokinetics of the drugs, studies need to be performed to determine the most suitable dose and dosage interval." | 2.46 | Pharmacokinetics of intravenous omeprazole in critically ill paediatric patients. ( López-Herce, J; Solana, MJ, 2010) |
| " This suggests that for stress ulcer prophylaxis, intermittent dosing with an intravenous proton pump inhibitor may be an alternative to high-dose continuous infusions of a histamine-2-receptor antagonist." | 2.41 | Stress-related mucosal disease in the critically ill patient: risk factors and strategies to prevent stress-related bleeding in the intensive care unit. ( Steinberg, KP, 2002) |
| "Omeprazole was delivered in bicarbonate suspension through a nasogastric tube." | 1.31 | Omeprozole therapy in pediatric patients after liver and intestinal transplantation. ( Andersen, DA; Bergman, KL; Brown, CR; Davis, CK; Fox, IJ; Horslen, SP; Kaufman, SS; Langnas, AN; Lyden, ER; Olsen, KM; Shaw, BW; Sudan, DL, 2002) |
| "Omeprazole, 20 or 40 mg, was administered once daily with water through a nasogastric tube." | 1.30 | Nasogastric omeprazole: effects on gastric pH in critically Ill patients. ( Balaban, DH; Duckworth, CW; Peura, DA, 1997) |
| " The pharmacokinetic parameters of omeprazole were: systemic clearance, 0." | 1.29 | Pharmacokinetics of intravenous omeprazole in children. ( Andre, J; Baudouin, V; Bellaich, M; Faure, C; Jacqz-Aigrain, E; Navarro, J; Rohrlich, P, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (26.32) | 18.2507 |
| 2000's | 8 (42.11) | 29.6817 |
| 2010's | 5 (26.32) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Abu El-Ella, SS | 1 |
| El-Mekkawy, MS | 1 |
| Mohamed Selim, A | 1 |
| Foroutan, N | 1 |
| Fahimi, F | 1 |
| Dabiri, Y | 1 |
| Foroutan, A | 1 |
| Habibi, M | 1 |
| Salamzadeh, J | 1 |
| Solana, MJ | 4 |
| Colom, H | 1 |
| López-Herce, J | 4 |
| Urbano, J | 3 |
| González, R | 1 |
| López, J | 1 |
| Manzanares, C | 1 |
| Carrillo, A | 2 |
| Gursoy, O | 1 |
| Memiş, D | 1 |
| Sut, N | 1 |
| Botrán, M | 1 |
| Del Castillo, J | 1 |
| Garrido, B | 1 |
| Sánchez, A | 1 |
| Sánchez, C | 1 |
| López, D | 1 |
| Yang, YX | 1 |
| Lewis, JD | 1 |
| Maton, PN | 1 |
| Jacqz-Aigrain, E | 1 |
| Bellaich, M | 1 |
| Faure, C | 1 |
| Andre, J | 1 |
| Rohrlich, P | 1 |
| Baudouin, V | 1 |
| Navarro, J | 1 |
| Balaban, DH | 1 |
| Duckworth, CW | 1 |
| Peura, DA | 1 |
| Levy, MJ | 1 |
| Seelig, CB | 1 |
| Robinson, NJ | 1 |
| Ranney, JE | 1 |
| Tsai, WL | 1 |
| Poon, SK | 1 |
| Yu, HK | 1 |
| Chang, CS | 1 |
| Yeh, HZ | 1 |
| Ko, CW | 1 |
| Chen, GH | 1 |
| Phillips, JO | 1 |
| Olsen, KM | 2 |
| Rebuck, JA | 1 |
| Rangnekar, NJ | 1 |
| Miedema, BW | 1 |
| Metzler, MH | 1 |
| Laterre, PF | 1 |
| Horsmans, Y | 1 |
| Kaufman, SS | 1 |
| Lyden, ER | 1 |
| Brown, CR | 1 |
| Davis, CK | 1 |
| Andersen, DA | 1 |
| Bergman, KL | 1 |
| Horslen, SP | 1 |
| Sudan, DL | 1 |
| Fox, IJ | 1 |
| Shaw, BW | 1 |
| Langnas, AN | 1 |
| Steinberg, KP | 1 |
| Brunner, GH | 1 |
| Thiesemann, C | 1 |
| Barie, PS | 1 |
| Hariri, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Esomeprazole and Famotidine for Stress Ulcer Prophylaxis in Neurosurgical Intensive Care Unit[NCT00633035] | Phase 4 | 60 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| Laparoscopic Revision Gastric Bypass Surgery for Perforated Marginal Ulcer: A 10 Year Experience[NCT01041196] | 30 participants (Actual) | Observational | 2009-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for omeprazole and Critical Illness
| Article | Year |
|---|---|
Pharmacokinetics of intravenous omeprazole in critically ill paediatric patients.
Topics: Child; Critical Illness; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Humans; Infusions, | 2010 |
Prevention and treatment of stress ulcers in critically ill patients.
Topics: Aged; Anti-Ulcer Agents; Cimetidine; Critical Illness; Female; Gastric Mucosa; Gastrointestinal Hemo | 2003 |
Review article: prevention of stress-related mucosal bleeding with proton-pump inhibitors.
Topics: Critical Illness; Enzyme Inhibitors; Gastric Mucosa; Gastrointestinal Hemorrhage; Humans; Omeprazole | 2005 |
Stress-related mucosal disease in the critically ill patient: risk factors and strategies to prevent stress-related bleeding in the intensive care unit.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Critical Illness; Gastric Mucosa; Gastroint | 2002 |
9 trials available for omeprazole and Critical Illness
| Article | Year |
|---|---|
Population pharmacokinetics of omeprazole in critically ill pediatric patients.
Topics: Area Under Curve; Body Weight; Child; Child, Preschool; Critical Illness; Dose-Response Relationship | 2014 |
Effect of proton pump inhibitors on gastric juice volume, gastric pH and gastric intramucosal pH in critically ill patients : a randomized, double-blind, placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Critical Illness; Double-Blind Method; Esomepr | 2008 |
[Hemodynamic effects of intravenous omeprazole in critically ill children].
Topics: Adolescent; Child; Child, Preschool; Critical Illness; Female; Hemodynamics; Humans; Infant; Infusio | 2013 |
0.5 mg/kg versus 1 mg/kg of intravenous omeprazole for the prophylaxis of gastrointestinal bleeding in critically ill children: a randomized study.
Topics: Anti-Ulcer Agents; Child; Child, Preschool; Critical Illness; Female; Gastric Acidity Determination; | 2013 |
Comparison of omeprazole and ranitidine for stress ulcer prophylaxis.
Topics: Anti-Ulcer Agents; APACHE; Critical Illness; Feasibility Studies; Female; Humans; Male; Middle Aged; | 1997 |
Nasogastric lansoprazole is effective in suppressing gastric acid secretion in critically ill patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Critical Illnes | 2000 |
A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers.
Topics: Adult; Anti-Ulcer Agents; Critical Illness; Cross-Over Studies; Duodenum; Female; Humans; Intubation | 2001 |
Intravenous omeprazole in critically ill patients: a randomized, crossover study comparing 40 with 80 mg plus 8 mg/hour on intragastric pH.
Topics: Adult; Critical Illness; Cross-Over Studies; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fe | 2001 |
The potential clinical role of intravenous omeprazole.
Topics: Critical Illness; Decision Trees; Female; Gastric Acidity Determination; Gastrointestinal Hemorrhage | 1992 |
6 other studies available for omeprazole and Critical Illness
| Article | Year |
|---|---|
Stress ulcer prophylaxis for critically ill children: routine use needs to be re-examined.
Topics: Acute Disease; Child; Critical Illness; Gastrointestinal Hemorrhage; Humans; Omeprazole; Peptic Ulce | 2022 |
BUDGET IMPACT ANALYSIS OF USING OMEPRAZOLE IMMEDIATE-RELEASE ORAL SUSPENSION IN REPLACE OF INTRAVENOUS PANTOPRAZOLE IN CRITICALLY ILL PATIENTS.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Critical Illness; Drug Costs; Humans; | 2015 |
Pharmacokinetics of intravenous omeprazole in children.
Topics: Adolescent; Adult; Child; Child, Preschool; Critical Illness; Esophagitis; Gastric Acidity Determina | 1994 |
Nasogastric omeprazole: effects on gastric pH in critically Ill patients.
Topics: Adult; Aged; Anti-Ulcer Agents; Costs and Cost Analysis; Critical Care; Critical Illness; Female; Ga | 1997 |
Omeprozole therapy in pediatric patients after liver and intestinal transplantation.
Topics: Anti-Ulcer Agents; Child; Child, Preschool; Critical Illness; Dose-Response Relationship, Drug; Fema | 2002 |
Therapeutic use of omeprazole for refractory stress-induced gastric mucosal hemorrhage.
Topics: Adult; Critical Illness; Disseminated Intravascular Coagulation; Gastrointestinal Hemorrhage; Humans | 1992 |